These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35528817)

  • 1. Live, Genetically Attenuated, Cold-Chain-Free Cholera Vaccine-A Research and Development Journey: Light at the End of a Long Tunnel.
    Ravichandran M; Tew HX; Prabhakaran G; Parasuraman S; Norazmi MN
    Malays J Med Sci; 2022 Apr; 29(2):1-7. PubMed ID: 35528817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
    Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
    BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M; Cheong TG; Kurunathan S; Chandrika M; Ledon T; Fando R; Lalitha P; Zainuddin ZF; Ravichandran M
    Microb Pathog; 2010 Nov; 49(5):211-6. PubMed ID: 20558271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation.
    Ravichandran M; Ali SA; Rashid NH; Kurunathan S; Yean CY; Ting LC; Bakar AS; Lalitha P; Zainuddin ZF
    Vaccine; 2006 May; 24(18):3750-61. PubMed ID: 16102875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated dose toxicity evaluation of a cold chain-free, live, attenuated oral cholera vaccine in Sprague Dawley rats.
    Xian TH; Parasuraman S; Sinniah K; Ravichandran M; Prabhakaran G
    Vaccine; 2019 Jan; 37(5):711-720. PubMed ID: 30630696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of Vibrio cholerae O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates.
    Singh DV; Matte MH; Matte GR; Jiang S; Sabeena F; Shukla BN; Sanyal SC; Huq A; Colwell RR
    Appl Environ Microbiol; 2001 Feb; 67(2):910-21. PubMed ID: 11157262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.
    Waldor MK; Mekalanos JJ
    J Infect Dis; 1994 Aug; 170(2):278-83. PubMed ID: 8035010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live attenuated oral cholera vaccines.
    Ryan ET; Calderwood SB; Qadri F
    Expert Rev Vaccines; 2006 Aug; 5(4):483-94. PubMed ID: 16989629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of rtxA and rtxC mutants of auxotrophic O139 Vibrio cholerae.
    Cheong TG; Chan M; Kurunathan S; Ali SA; ZiNing T; Zainuddin ZF; Lalitha P; Ravichandran M
    Microb Pathog; 2010 Feb; 48(2):85-90. PubMed ID: 19900531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
    Coster TS; Killeen KP; Waldor MK; Beattie DT; Spriggs DR; Kenner JR; Trofa A; Sadoff JC; Mekalanos JJ; Taylor DN
    Lancet; 1995 Apr; 345(8955):949-52. PubMed ID: 7715293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The state-of-the-art of approved and under-development cholera vaccines.
    Pastor M; Pedraz JL; Esquisabel A
    Vaccine; 2013 Aug; 31(38):4069-78. PubMed ID: 23845813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera.
    Ledón T; Ferrán B; Pérez C; Suzarte E; Vichi J; Marrero K; Oliva R; Fando R
    Microbes Infect; 2012 Sep; 14(11):968-78. PubMed ID: 22546527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.